Researchers evaluated the efficacy and safety of guselkumab in patients with active psoriatic arthritis who were biologic-naive or treated with prior tumor necrosis factor inhibitors.
Mepolizumab reduced the number of exacerbations in patients with severe asthma, but exacerbations per month remained relatively stable throughout the year without a clear seasonal influence.
The clinician workgroup achieved a consensus and report a 3-step iterative management algorithm for MS relapses.
Treating osteoarthritis in older patients with tramadol vs nonsteroidal anti-inflammatory drugs may be associated with an increased mortality rate during the year following treatment initiation.
Management is generally in a stepwise manner, including moisturizers and avoiding triggers
The patients began treatment with oral sirolimus; after 1 year of treatment, there was improvement in exertional dyspnea in all 3 patients.
The researchers found that the median duration of cough was 5 days in both the prednisolone and placebo groups (adjusted hazard ratio, 1.11; 95% confidence interval, 0.89 to 1.39; P=0.36).
Diffuse, persistent, pruritic maculopapular rash developed 10 days after tocilizumab treatment
General consensus supporting early multimodality treatment for infantile hemangiomas of the nose
The team found no significant differences between the three groups of children who received topical steroid, emollient, or placebo in terms of Patient Oriented Eczema Measure scores.
